These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 27801751)

  • 1. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
    Greuter T; Bertoldo F; Rechner R; Straumann A; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Rogler G; Safroneeva E; Ali RAR; Braegger C; Heyland K; Mueller P; Nydegger A; Petit LM; Schibli S; Furlano RI; Spalinger J; Schäppi M; Zamora S; Froehlich F; Herzog D; Schoepfer AM; Vavricka SR;
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):200-206. PubMed ID: 27801751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
    Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
    Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.
    Hiller A; Biedermann L; Fournier N; Butter M; Vavricka SR; Ciurea A; Rogler G; Scharl M;
    PLoS One; 2019; 14(4):e0211554. PubMed ID: 31039159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of extraintestinal manifestations in inflammatory bowel disease.
    Lakatos PL; Lakatos L; Kiss LS; Peyrin-Biroulet L; Schoepfer A; Vavricka S
    Digestion; 2012; 86 Suppl 1():28-35. PubMed ID: 23051724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
    Vavricka SR; Gubler M; Gantenbein C; Spoerri M; Froehlich F; Seibold F; Protic M; Michetti P; Straumann A; Fournier N; Juillerat P; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Heinrich H; Manser CN; Safroneeva E; Raja Ali RA; Rogler G; Schoepfer AM; Greuter T;
    Inflamm Bowel Dis; 2017 Jul; 23(7):1174-1181. PubMed ID: 28452862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.
    Jose FA; Garnett EA; Vittinghoff E; Ferry GD; Winter HS; Baldassano RN; Kirschner BS; Cohen SA; Gold BD; Abramson O; Heyman MB
    Inflamm Bowel Dis; 2009 Jan; 15(1):63-8. PubMed ID: 18626963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extra-intestinal manifestation of IBD in Veszprém county (of Hungary): results of a 25-years follow-up study].
    Lakatos L; Pandur T; Dávid G; Balogh Z; Küronya P; Tollas A; Lakatos PL
    Orv Hetil; 2003 Oct; 144(40):1965-75. PubMed ID: 14626638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort.
    Isene R; Bernklev T; Høie O; Munkholm P; Tsianos E; Stockbrügger R; Odes S; Palm Ø; Småstuen M; Moum B;
    Scand J Gastroenterol; 2015 Mar; 50(3):300-5. PubMed ID: 25535653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
    Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Khrom M; Long M; Dube S; Robbins L; Botwin GJ; Yang S; Mengesha E; Li D; Naito T; Bonthala NN; Ha C; Melmed G; Rabizadeh S; Syal G; Vasiliauskas E; Ziring D; Brant SR; Cho J; Duerr RH; Rioux J; Schumm P; Silverberg M; Ananthakrishnan AN; Faubion WA; Jabri B; Lira SA; Newberry RD; Sandler RS; Xavier RJ; Kugathasan S; Hercules D; Targan SR; Sartor RB; Haritunians T; McGovern DPB
    Gastroenterology; 2024 Jul; 167(2):315-332. PubMed ID: 38490347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
    Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
    PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease].
    Stawarski A; Iwańczak B; Krzesiek E; Iwańczak F
    Pol Merkur Lekarski; 2006 Jan; 20(115):22-5. PubMed ID: 16617729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
    Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study.
    Lakatos L; Pandur T; David G; Balogh Z; Kuronya P; Tollas A; Lakatos PL
    World J Gastroenterol; 2003 Oct; 9(10):2300-7. PubMed ID: 14562397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
    Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
    Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease.
    Matar M; Rinawi F; Shamir R; Assa A
    Turk J Gastroenterol; 2017 Mar; 28(2):131-134. PubMed ID: 28124661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics for extraintestinal manifestations of IBD.
    Vavricka SR; Scharl M; Gubler M; Rogler G
    Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and clinical features of chronic uveitis in pediatric inflammatory bowel diseases: A nationwide study.
    Maniscalco V; Scarallo L; Aloi M; Alvisi P; Norsa L; Zuin G; Simonini G; Lionetti P
    J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1305-1309. PubMed ID: 38594804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.